Table 1.
Clinical and pathological features of the patients diagnosed with bladder Carcinoma
| Case no. | @Age/ $Gender | Stage | Grade | #Recurrence | MSI |
| BC 1 | 45/M | T2 | High, G3 | 2 | *High (BAT – 26, BAT – 40) |
| BC 2 | 59/M | T1 | High, G2 | 1 | High (BAT – 26, BAT – 40, D9S1851) |
| BC 3 | 66/M | Ta | Low, G1 | 0 | High (D9S283, D9S1851) |
| BC 4 | 39/M | T2 | High, G3 | 0 | High (BAT – 26, BAT – 40, D9S283) |
| BC 5 | 72/M | T2 | High, G3 | 0 | High (BAT – 40, D9S1851) |
| BC 6 | 59/M | T2 | High, G2 | 1 | Low (D9S1851) |
| BC 7 | 78/M | T2 | High, G3 | 0 | High (D9S283, D9S1851) |
| BC 8 | 52/M | Ta | High, G2 | 0 | High (BAT – 40, D9S283, D9S1851) |
| BC 9 | 71/M | Ta | High, G2 | 0 | **Low (BAT – 40) |
| BC 10 | 84/M | T1 | High, G2 | 0 | ***MSS |
| BC 11 | 55/M | T1 | High, G1 | 0 | MSS |
| BC 12 | 53/M | T2 | High, G2 | 0 | Low (D18S58) |
| BC 13 | 52/M | T3 | High, G3 | 0 | High (D9S283, D9S1851) |
| BC 14 | 40/M | T3 | High, G3 | 0 | MSS |
| BC 15 | 55/M | T2 | High, G3 | 0 | MSS |
| BC 16 | 60/M | T2 | High, G3 | 0 | High (BAT – 40, D9S283, D18S58) |
| BC 17 | 66/M | T1 | High, G3 | 1 | High (BAT – 40, D2S123, D9S283, D9S1851, D18S58) |
| BC 18 | 80/M | T1 | High, G3 | 1 | High (BAT – 26, D9S283, D18S58) |
| BC 19 | 42/M | T1 | High, G2 | 0 | Low (D9S283) |
| BC 20 | 73/M | T3a | High, G3 | 0 | MSS |
| BC 21 | 55/M | T2 | High, G3 | 0 | Low (D2S123) |
| BC 22 | 58/M | T2 | High, G3 | 0 | High (BAT – 26, D2S123) |
| BC 23 | 70/M | T1 | High, G2 | 0 | Low (BAT – 26) |
| BC 24 | 53/M | Ta | High, G3 | 0 | High (D9S1851, D18S58) |
| BC 25 | 60/M | T2 | High, G3 | 0 | High (D9S283, D9S1851) |
| BC 26 | 54/M | Ta | Low, G1 | 0 | MSS |
| BC 27 | 72/M | Ta | High, G2 | 0 | MSS |
| BC 28 | 58/M | T1 | High, G3 | 0 | Low (D9S283) |
| BC 29 | 80/M | T2 | High, G3 | 0 | High (D9S283, D9S1851) |
| BC 30 | 64/M | Ta | High, G2 | 2 | Low (BAT – 40) |
| BC 31 | 74/M | Ta | High, G3 | 0 | High (D9S283, D9S1851) |
| BC 32 | 60/M | T1 | Low, G1 | 0 | MSS |
| BC 33 | 41/M | T1 | Low, G1 | 3 | Low (BAT – 26) |
| BC 34 | 66/ F | T2 | High, G3 | 0 | High (D2S123, D9S283) |
| BC 35 | 53/M | T1 | Low, G1 | 0 | Low (D2S123) |
| BC 36 | 66/M | T1 | High, G2 | 1 | High (D2S123, D9S283, D18S58) |
| BC 37 | 55/M | T2 | High, G3 | 0 | High (BAT – 26, BAT – 40, D9S1851) |
| BC 38 | 65/M | T2 | High, G3 | 0 | Low (D18S58) |
| BC 39 | 69/M | T1 | Low, G1 | 0 | Low (D9S283) |
| BC 40 | 74/M | T1 | High, G2 | 1 | MSS |
| BC 41 | 72/ F | T2 | Low, G1 | 0 | MSS |
| BC 42 | 71/M | T1 | High, G3 | 1 | Low (D9S283) |
| BC 43 | 64/M | T2 | High, G3 | 0 | High (BAT – 40, D9S1851) |
| BC 44 | 73/M | T1 | High, G2 | 1 | Low (D9S283) |
@Age = (years); $Gender = (M: Male/F: Female); *MSI – H = MSI – High; **MSI – L = MSI – Low; ***MSS = microsatellite stable
# Recurrence (0, 1, 2, 3) = Number of times the tumor recurred